Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Ovarian Neoplasms | 57 | 2024 | 4907 | 2.940 |
Why?
|
Peritoneal Neoplasms | 12 | 2024 | 715 | 1.200 |
Why?
|
Endometrial Neoplasms | 10 | 2021 | 1382 | 1.140 |
Why?
|
Neoplastic Syndromes, Hereditary | 2 | 2019 | 249 | 0.930 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 33 | 2020 | 11854 | 0.920 |
Why?
|
Genital Neoplasms, Female | 5 | 2023 | 539 | 0.840 |
Why?
|
Neoplasm Recurrence, Local | 26 | 2020 | 9433 | 0.810 |
Why?
|
Taxoids | 10 | 2013 | 668 | 0.760 |
Why?
|
Paclitaxel | 20 | 2014 | 1736 | 0.710 |
Why?
|
Gynecologic Surgical Procedures | 5 | 2014 | 289 | 0.680 |
Why?
|
Diaphragm | 5 | 2013 | 359 | 0.650 |
Why?
|
Cystadenocarcinoma, Serous | 4 | 2024 | 480 | 0.640 |
Why?
|
Vulvar Neoplasms | 4 | 2022 | 266 | 0.590 |
Why?
|
Neoplasm Staging | 31 | 2024 | 11254 | 0.530 |
Why?
|
Neoplasms, Glandular and Epithelial | 6 | 2015 | 489 | 0.530 |
Why?
|
Fallopian Tube Neoplasms | 7 | 2024 | 329 | 0.530 |
Why?
|
Antineoplastic Agents, Phytogenic | 6 | 2000 | 622 | 0.490 |
Why?
|
Pelvic Exenteration | 3 | 2014 | 22 | 0.490 |
Why?
|
Antineoplastic Agents | 22 | 2016 | 13697 | 0.470 |
Why?
|
Camptothecin | 3 | 2004 | 593 | 0.450 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2016 | 259 | 0.430 |
Why?
|
Neoplasm, Residual | 4 | 2014 | 1019 | 0.430 |
Why?
|
Angiogenesis Inhibitors | 4 | 2015 | 2060 | 0.430 |
Why?
|
Uterine Cervical Neoplasms | 8 | 2020 | 2044 | 0.380 |
Why?
|
Laparotomy | 2 | 2016 | 459 | 0.350 |
Why?
|
Carboplatin | 11 | 2014 | 799 | 0.340 |
Why?
|
Neoadjuvant Therapy | 4 | 2023 | 2909 | 0.330 |
Why?
|
Drug Administration Schedule | 21 | 2013 | 4859 | 0.320 |
Why?
|
Lymph Node Excision | 7 | 2022 | 1274 | 0.320 |
Why?
|
Female | 119 | 2024 | 397089 | 0.300 |
Why?
|
Risk Reduction Behavior | 1 | 2014 | 1118 | 0.290 |
Why?
|
Molecular Targeted Therapy | 2 | 2020 | 2830 | 0.290 |
Why?
|
Surgical Procedures, Operative | 1 | 2019 | 1937 | 0.290 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 11 | 2001 | 5422 | 0.290 |
Why?
|
Genetic Predisposition to Disease | 3 | 2020 | 18048 | 0.280 |
Why?
|
Hysterectomy | 5 | 2021 | 864 | 0.280 |
Why?
|
Dacarbazine | 2 | 2006 | 560 | 0.280 |
Why?
|
Uterine Neoplasms | 3 | 2024 | 1427 | 0.280 |
Why?
|
Middle Aged | 87 | 2024 | 223491 | 0.270 |
Why?
|
Aged | 78 | 2024 | 171562 | 0.270 |
Why?
|
Protein Kinase Inhibitors | 2 | 2024 | 5708 | 0.270 |
Why?
|
Mixed Tumor, Mullerian | 1 | 2006 | 55 | 0.260 |
Why?
|
Phosphorylcholine | 1 | 2006 | 153 | 0.260 |
Why?
|
Carcinoma, Endometrioid | 2 | 2021 | 276 | 0.260 |
Why?
|
Muscle Neoplasms | 1 | 2006 | 130 | 0.250 |
Why?
|
Disease-Free Survival | 15 | 2015 | 6856 | 0.250 |
Why?
|
Abdominal Fat | 1 | 2007 | 221 | 0.250 |
Why?
|
Early Detection of Cancer | 1 | 2019 | 3236 | 0.240 |
Why?
|
Pleural Effusion | 2 | 2013 | 344 | 0.230 |
Why?
|
Adult | 76 | 2024 | 223640 | 0.230 |
Why?
|
Combined Modality Therapy | 13 | 2014 | 8562 | 0.230 |
Why?
|
Antineoplastic Agents, Alkylating | 2 | 2006 | 618 | 0.220 |
Why?
|
Leiomyosarcoma | 2 | 2021 | 425 | 0.220 |
Why?
|
Infusions, Intravenous | 10 | 2011 | 2226 | 0.220 |
Why?
|
Anthraquinones | 2 | 1993 | 41 | 0.220 |
Why?
|
Humans | 125 | 2024 | 768393 | 0.220 |
Why?
|
Cystadenocarcinoma, Papillary | 1 | 2023 | 56 | 0.220 |
Why?
|
Antibiotics, Antineoplastic | 5 | 2000 | 677 | 0.210 |
Why?
|
Guanine | 2 | 2001 | 280 | 0.210 |
Why?
|
Ovariectomy | 3 | 2014 | 615 | 0.210 |
Why?
|
Lung Neoplasms | 14 | 2001 | 13576 | 0.210 |
Why?
|
Immunotherapy | 1 | 2018 | 4738 | 0.200 |
Why?
|
Survival Rate | 18 | 2018 | 12870 | 0.200 |
Why?
|
Galectin 3 | 1 | 2024 | 240 | 0.200 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2024 | 664 | 0.180 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2022 | 740 | 0.170 |
Why?
|
Topotecan | 6 | 2013 | 131 | 0.170 |
Why?
|
Doxorubicin | 3 | 2012 | 2229 | 0.170 |
Why?
|
Cisplatin | 9 | 2013 | 1661 | 0.170 |
Why?
|
Interferon-alpha | 4 | 2000 | 910 | 0.170 |
Why?
|
Receptors, Growth Factor | 1 | 2001 | 326 | 0.170 |
Why?
|
Home Care Services, Hospital-Based | 1 | 2020 | 45 | 0.170 |
Why?
|
Phenyl Ethers | 1 | 1999 | 62 | 0.170 |
Why?
|
Deoxycytidine | 4 | 2014 | 888 | 0.170 |
Why?
|
Lymph Nodes | 3 | 2022 | 3471 | 0.170 |
Why?
|
Melanoma | 1 | 2018 | 5705 | 0.170 |
Why?
|
Histamine Antagonists | 1 | 1999 | 94 | 0.160 |
Why?
|
Sarcoma | 2 | 2006 | 1807 | 0.160 |
Why?
|
Medical Oncology | 3 | 2024 | 2349 | 0.160 |
Why?
|
Ifosfamide | 4 | 1998 | 234 | 0.160 |
Why?
|
Blood Proteins | 1 | 2024 | 1186 | 0.150 |
Why?
|
Aged, 80 and over | 22 | 2021 | 59686 | 0.150 |
Why?
|
Organoplatinum Compounds | 4 | 2010 | 408 | 0.150 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2001 | 640 | 0.150 |
Why?
|
Neoplasms | 8 | 2006 | 22385 | 0.150 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2021 | 365 | 0.150 |
Why?
|
Treatment Outcome | 30 | 2020 | 65379 | 0.150 |
Why?
|
Tretinoin | 1 | 2000 | 525 | 0.140 |
Why?
|
Maximum Tolerated Dose | 2 | 2014 | 890 | 0.140 |
Why?
|
Canada | 8 | 2006 | 2139 | 0.140 |
Why?
|
Depsipeptides | 1 | 1998 | 96 | 0.140 |
Why?
|
Ontario | 1 | 2018 | 403 | 0.140 |
Why?
|
Robotics | 2 | 2015 | 825 | 0.140 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2013 | 5336 | 0.140 |
Why?
|
Radiation-Sensitizing Agents | 1 | 1999 | 349 | 0.140 |
Why?
|
Drug Discovery | 1 | 2024 | 1067 | 0.130 |
Why?
|
Survival Analysis | 9 | 2012 | 10117 | 0.130 |
Why?
|
Retrospective Studies | 24 | 2024 | 81801 | 0.130 |
Why?
|
Leiomyoma | 1 | 2021 | 644 | 0.130 |
Why?
|
Genetic Counseling | 1 | 2020 | 634 | 0.130 |
Why?
|
Aminoquinolines | 1 | 2016 | 105 | 0.130 |
Why?
|
Obesity, Morbid | 1 | 2007 | 1309 | 0.130 |
Why?
|
Paget Disease, Extramammary | 1 | 2016 | 51 | 0.130 |
Why?
|
Leukemia, Myeloid | 1 | 1999 | 693 | 0.130 |
Why?
|
Dose-Response Relationship, Drug | 10 | 2011 | 10776 | 0.130 |
Why?
|
Peptides, Cyclic | 1 | 1998 | 391 | 0.130 |
Why?
|
Mitogen-Activated Protein Kinase Kinases | 1 | 2018 | 637 | 0.120 |
Why?
|
Laparoscopy | 1 | 2007 | 2056 | 0.120 |
Why?
|
DNA Repair | 1 | 2024 | 2048 | 0.120 |
Why?
|
Statistics as Topic | 1 | 2001 | 2363 | 0.120 |
Why?
|
Precancerous Conditions | 1 | 2021 | 984 | 0.120 |
Why?
|
New York City | 2 | 2006 | 737 | 0.110 |
Why?
|
Vaginal Neoplasms | 1 | 2014 | 105 | 0.110 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2020 | 957 | 0.110 |
Why?
|
Aminoglycosides | 1 | 1994 | 161 | 0.110 |
Why?
|
Histone Deacetylase 1 | 1 | 2013 | 133 | 0.110 |
Why?
|
Social Support | 1 | 2023 | 2191 | 0.110 |
Why?
|
Pyrazoles | 2 | 1993 | 2021 | 0.100 |
Why?
|
Benzhydryl Compounds | 1 | 1999 | 940 | 0.100 |
Why?
|
Agranulocytosis | 3 | 2000 | 98 | 0.100 |
Why?
|
Parity | 1 | 2016 | 938 | 0.100 |
Why?
|
Piperidones | 1 | 2012 | 37 | 0.100 |
Why?
|
Colostomy | 1 | 2012 | 106 | 0.100 |
Why?
|
BRCA1 Protein | 2 | 2024 | 1155 | 0.100 |
Why?
|
Perioperative Care | 1 | 2020 | 1045 | 0.100 |
Why?
|
Prognosis | 7 | 2024 | 30022 | 0.100 |
Why?
|
Urinary Diversion | 1 | 2012 | 137 | 0.100 |
Why?
|
Psychometrics | 1 | 2021 | 3069 | 0.100 |
Why?
|
Immunologic Factors | 1 | 2000 | 1597 | 0.090 |
Why?
|
Astrocytoma | 1 | 1996 | 780 | 0.090 |
Why?
|
Reproduction | 1 | 2016 | 646 | 0.090 |
Why?
|
Carcinoma | 2 | 2001 | 2341 | 0.090 |
Why?
|
Fertility | 1 | 2016 | 772 | 0.090 |
Why?
|
Pentostatin | 2 | 2000 | 26 | 0.090 |
Why?
|
Intraoperative Care | 1 | 2014 | 771 | 0.090 |
Why?
|
Splenectomy | 2 | 2008 | 392 | 0.090 |
Why?
|
Leukemia, Hairy Cell | 2 | 2000 | 82 | 0.090 |
Why?
|
Isoxazoles | 3 | 1990 | 233 | 0.090 |
Why?
|
Neoplasm Invasiveness | 2 | 2016 | 3633 | 0.090 |
Why?
|
Palliative Care | 4 | 2018 | 3643 | 0.080 |
Why?
|
Documentation | 1 | 2016 | 917 | 0.080 |
Why?
|
Breast Neoplasms | 5 | 2006 | 21162 | 0.080 |
Why?
|
Intestinal Obstruction | 1 | 2013 | 435 | 0.080 |
Why?
|
Glutamates | 2 | 2001 | 385 | 0.080 |
Why?
|
Chemotherapy, Adjuvant | 5 | 2023 | 3553 | 0.080 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2013 | 342 | 0.080 |
Why?
|
Injections, Intravenous | 5 | 2006 | 1379 | 0.080 |
Why?
|
Drug Therapy, Combination | 2 | 2014 | 6318 | 0.080 |
Why?
|
Intercellular Signaling Peptides and Proteins | 1 | 2016 | 1658 | 0.080 |
Why?
|
Feasibility Studies | 4 | 2014 | 5313 | 0.080 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2018 | 2058 | 0.080 |
Why?
|
Follow-Up Studies | 7 | 2016 | 39407 | 0.080 |
Why?
|
CA-125 Antigen | 2 | 2009 | 281 | 0.080 |
Why?
|
Prospective Studies | 10 | 2023 | 54920 | 0.070 |
Why?
|
Carcinoma, Small Cell | 3 | 1999 | 420 | 0.070 |
Why?
|
STAT3 Transcription Factor | 1 | 2012 | 875 | 0.070 |
Why?
|
Quality of Life | 9 | 2023 | 13503 | 0.070 |
Why?
|
Etoposide | 3 | 1999 | 639 | 0.070 |
Why?
|
Pancreatic Fistula | 1 | 2008 | 149 | 0.070 |
Why?
|
Decompression, Surgical | 1 | 2013 | 610 | 0.070 |
Why?
|
Healthcare Disparities | 1 | 2023 | 3413 | 0.070 |
Why?
|
Disease Progression | 6 | 2013 | 13646 | 0.070 |
Why?
|
Pancreatectomy | 2 | 2008 | 824 | 0.070 |
Why?
|
Kidney Neoplasms | 3 | 2000 | 4303 | 0.070 |
Why?
|
Carcinoma, Renal Cell | 2 | 2000 | 3200 | 0.070 |
Why?
|
Neoplasm Metastasis | 3 | 2006 | 4921 | 0.070 |
Why?
|
Databases, Factual | 3 | 2008 | 8075 | 0.070 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1409 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2022 | 4069 | 0.070 |
Why?
|
Abdominal Neoplasms | 1 | 2008 | 287 | 0.070 |
Why?
|
Referral and Consultation | 2 | 2020 | 3627 | 0.070 |
Why?
|
Omentum | 1 | 2007 | 168 | 0.070 |
Why?
|
Oxazoles | 2 | 1986 | 199 | 0.070 |
Why?
|
Anxiety | 1 | 2021 | 4677 | 0.070 |
Why?
|
Carmustine | 1 | 2006 | 137 | 0.070 |
Why?
|
Male | 31 | 2018 | 364902 | 0.070 |
Why?
|
Remission Induction | 4 | 2000 | 2407 | 0.060 |
Why?
|
Infusions, Parenteral | 3 | 2006 | 397 | 0.060 |
Why?
|
Young Adult | 6 | 2021 | 60049 | 0.060 |
Why?
|
Lymphatic Metastasis | 3 | 2022 | 2925 | 0.060 |
Why?
|
Nomograms | 1 | 2007 | 236 | 0.060 |
Why?
|
Brain Neoplasms | 3 | 1996 | 9198 | 0.060 |
Why?
|
Abdomen | 2 | 2008 | 1136 | 0.060 |
Why?
|
Pain, Postoperative | 1 | 2016 | 1765 | 0.060 |
Why?
|
Peritoneum | 1 | 2006 | 231 | 0.060 |
Why?
|
Proto-Oncogene Proteins | 2 | 2016 | 4526 | 0.060 |
Why?
|
Academies and Institutes | 1 | 2006 | 326 | 0.060 |
Why?
|
Platinum Compounds | 2 | 2009 | 95 | 0.060 |
Why?
|
DNA Damage | 1 | 2013 | 2458 | 0.060 |
Why?
|
Cohort Studies | 6 | 2022 | 41795 | 0.050 |
Why?
|
Postoperative Care | 2 | 2007 | 1480 | 0.050 |
Why?
|
Neutropenia | 4 | 2000 | 893 | 0.050 |
Why?
|
Half-Life | 1 | 2004 | 650 | 0.050 |
Why?
|
Drug Evaluation | 6 | 1992 | 642 | 0.050 |
Why?
|
Thionucleotides | 1 | 2003 | 107 | 0.050 |
Why?
|
Glioblastoma | 2 | 1996 | 3526 | 0.050 |
Why?
|
Rad51 Recombinase | 1 | 2024 | 191 | 0.050 |
Why?
|
Oligodeoxyribonucleotides, Antisense | 1 | 2003 | 57 | 0.050 |
Why?
|
Inpatients | 1 | 2015 | 2570 | 0.050 |
Why?
|
Length of Stay | 2 | 2015 | 6519 | 0.050 |
Why?
|
Prevalence | 1 | 2019 | 15872 | 0.050 |
Why?
|
Medical Records | 1 | 2007 | 1412 | 0.050 |
Why?
|
Kaplan-Meier Estimate | 3 | 2020 | 6541 | 0.050 |
Why?
|
Folic Acid Antagonists | 1 | 2001 | 74 | 0.050 |
Why?
|
Nausea | 3 | 2000 | 682 | 0.050 |
Why?
|
Galectins | 1 | 2024 | 296 | 0.050 |
Why?
|
Glioma | 1 | 1996 | 3526 | 0.040 |
Why?
|
Soft Tissue Neoplasms | 1 | 1989 | 1167 | 0.040 |
Why?
|
Endometrial Hyperplasia | 1 | 2021 | 99 | 0.040 |
Why?
|
Liposomes | 1 | 2004 | 792 | 0.040 |
Why?
|
Spleen | 1 | 2006 | 2296 | 0.040 |
Why?
|
Colorectal Neoplasms | 2 | 2006 | 6971 | 0.040 |
Why?
|
Area Under Curve | 1 | 2004 | 1642 | 0.040 |
Why?
|
Amifostine | 1 | 1999 | 40 | 0.040 |
Why?
|
Fever | 2 | 2013 | 1620 | 0.040 |
Why?
|
Apoptosis | 2 | 2013 | 9516 | 0.040 |
Why?
|
Analgesics, Opioid | 1 | 2016 | 3836 | 0.040 |
Why?
|
Radiation-Protective Agents | 1 | 1999 | 88 | 0.040 |
Why?
|
Pancreas | 1 | 2006 | 1702 | 0.040 |
Why?
|
Patient Selection | 2 | 2015 | 4266 | 0.040 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2021 | 218 | 0.040 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2024 | 608 | 0.040 |
Why?
|
Administration, Oral | 2 | 2006 | 4039 | 0.040 |
Why?
|
Salvage Therapy | 1 | 2006 | 1277 | 0.040 |
Why?
|
Nitriles | 1 | 2004 | 984 | 0.040 |
Why?
|
Structure-Activity Relationship | 1 | 2024 | 3055 | 0.040 |
Why?
|
Epirubicin | 2 | 2012 | 81 | 0.040 |
Why?
|
Membrane Proteins | 1 | 2016 | 7880 | 0.040 |
Why?
|
Triazoles | 1 | 2004 | 904 | 0.040 |
Why?
|
DNA Topoisomerases, Type II | 1 | 1999 | 121 | 0.040 |
Why?
|
United States | 6 | 2023 | 73150 | 0.040 |
Why?
|
Recombinant Proteins | 5 | 2000 | 6510 | 0.040 |
Why?
|
Carcinoma, Adenosquamous | 1 | 2017 | 67 | 0.040 |
Why?
|
Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2021 | 388 | 0.040 |
Why?
|
Quality Indicators, Health Care | 1 | 2007 | 1813 | 0.040 |
Why?
|
Cell Line, Tumor | 3 | 2024 | 17135 | 0.030 |
Why?
|
Diphenhydramine | 1 | 1996 | 63 | 0.030 |
Why?
|
Propensity Score | 1 | 2024 | 1962 | 0.030 |
Why?
|
Drug Synergism | 1 | 2000 | 1762 | 0.030 |
Why?
|
Postoperative Period | 2 | 2013 | 1830 | 0.030 |
Why?
|
Fatigue | 2 | 2000 | 1555 | 0.030 |
Why?
|
DNA-Binding Proteins | 1 | 2013 | 9614 | 0.030 |
Why?
|
Antiemetics | 1 | 1998 | 188 | 0.030 |
Why?
|
Risk Factors | 3 | 2019 | 74962 | 0.030 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2024 | 1536 | 0.030 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2013 | 1794 | 0.030 |
Why?
|
Retroperitoneal Space | 1 | 2016 | 173 | 0.030 |
Why?
|
Granulocytes | 1 | 1998 | 550 | 0.030 |
Why?
|
Paresthesia | 1 | 1996 | 160 | 0.030 |
Why?
|
Neoplasms, Second Primary | 2 | 2000 | 1060 | 0.030 |
Why?
|
Carcinoma in Situ | 1 | 2021 | 789 | 0.030 |
Why?
|
Ethics, Medical | 1 | 2001 | 785 | 0.030 |
Why?
|
Rectal Neoplasms | 1 | 1984 | 1188 | 0.030 |
Why?
|
Hematuria | 1 | 1996 | 233 | 0.030 |
Why?
|
Nephrectomy | 1 | 2000 | 949 | 0.030 |
Why?
|
Randomized Controlled Trials as Topic | 3 | 2017 | 10377 | 0.030 |
Why?
|
Radiography | 1 | 2006 | 6993 | 0.030 |
Why?
|
Anti-Bacterial Agents | 1 | 1994 | 7463 | 0.030 |
Why?
|
Drug Tolerance | 1 | 1996 | 366 | 0.030 |
Why?
|
Confusion | 1 | 1996 | 278 | 0.030 |
Why?
|
Liver | 2 | 2008 | 7574 | 0.030 |
Why?
|
Treatment Failure | 1 | 2000 | 2663 | 0.030 |
Why?
|
Models, Molecular | 1 | 2024 | 5404 | 0.030 |
Why?
|
Risk Assessment | 1 | 2016 | 24318 | 0.030 |
Why?
|
Administration, Topical | 1 | 2016 | 703 | 0.030 |
Why?
|
Diarrhea | 1 | 2000 | 1320 | 0.030 |
Why?
|
Pregnancy | 1 | 2016 | 30200 | 0.030 |
Why?
|
Clinical Trials as Topic | 3 | 2005 | 8051 | 0.030 |
Why?
|
Case-Control Studies | 2 | 2010 | 22296 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2017 | 876 | 0.030 |
Why?
|
Cell Proliferation | 2 | 2024 | 10478 | 0.030 |
Why?
|
Thoracostomy | 1 | 2013 | 79 | 0.030 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2001 | 1628 | 0.030 |
Why?
|
Extracellular Matrix | 1 | 2001 | 1739 | 0.030 |
Why?
|
Cyclic S-Oxides | 1 | 2012 | 25 | 0.030 |
Why?
|
Hematologic Tests | 1 | 1993 | 239 | 0.030 |
Why?
|
Arthralgia | 1 | 1996 | 459 | 0.030 |
Why?
|
Isotretinoin | 1 | 1994 | 134 | 0.030 |
Why?
|
Colonic Neoplasms | 1 | 1984 | 2544 | 0.030 |
Why?
|
Muscular Diseases | 1 | 1996 | 554 | 0.020 |
Why?
|
Forecasting | 2 | 2005 | 2948 | 0.020 |
Why?
|
Interleukin-3 | 1 | 1993 | 425 | 0.020 |
Why?
|
Parenteral Nutrition, Total | 1 | 2013 | 304 | 0.020 |
Why?
|
Cell Movement | 1 | 2024 | 5215 | 0.020 |
Why?
|
Postoperative Complications | 3 | 2016 | 15881 | 0.020 |
Why?
|
Chemokines | 1 | 2016 | 962 | 0.020 |
Why?
|
Ribavirin | 1 | 1993 | 395 | 0.020 |
Why?
|
Data Interpretation, Statistical | 1 | 2001 | 2708 | 0.020 |
Why?
|
Adjuvants, Immunologic | 1 | 2016 | 998 | 0.020 |
Why?
|
Cyclin D1 | 1 | 2012 | 453 | 0.020 |
Why?
|
Age Factors | 1 | 2007 | 18471 | 0.020 |
Why?
|
Cyclophosphamide | 2 | 2013 | 2226 | 0.020 |
Why?
|
Government Agencies | 1 | 1990 | 161 | 0.020 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 1994 | 646 | 0.020 |
Why?
|
Urinary Tract | 1 | 2013 | 305 | 0.020 |
Why?
|
DNA | 1 | 2024 | 7211 | 0.020 |
Why?
|
Sulfonylurea Compounds | 1 | 1992 | 220 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-akt | 2 | 2012 | 2460 | 0.020 |
Why?
|
Drug Design | 1 | 2015 | 1046 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2012 | 720 | 0.020 |
Why?
|
Pilot Projects | 2 | 2016 | 8731 | 0.020 |
Why?
|
Disease Management | 1 | 2020 | 2537 | 0.020 |
Why?
|
Hematologic Diseases | 3 | 1996 | 499 | 0.020 |
Why?
|
Dexamethasone | 1 | 1996 | 1965 | 0.020 |
Why?
|
Drug Hypersensitivity | 1 | 1998 | 923 | 0.020 |
Why?
|
Amylases | 1 | 2008 | 171 | 0.020 |
Why?
|
Bone Marrow | 1 | 1999 | 2929 | 0.020 |
Why?
|
Pain | 2 | 2000 | 5103 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8902 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 4588 | 0.020 |
Why?
|
Peritoneal Cavity | 1 | 2008 | 135 | 0.020 |
Why?
|
Genomics | 1 | 2024 | 5916 | 0.020 |
Why?
|
Blotting, Western | 1 | 2016 | 5037 | 0.020 |
Why?
|
Acute Disease | 1 | 1999 | 7242 | 0.020 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1991 | 892 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2016 | 6132 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2022 | 12558 | 0.020 |
Why?
|
Incidence | 1 | 2006 | 21544 | 0.020 |
Why?
|
BRCA2 Protein | 1 | 2012 | 802 | 0.020 |
Why?
|
Oncology Service, Hospital | 1 | 2007 | 57 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2000 | 4209 | 0.020 |
Why?
|
Ascites | 1 | 2008 | 338 | 0.020 |
Why?
|
Time Factors | 2 | 2009 | 40272 | 0.020 |
Why?
|
Vomiting | 2 | 2000 | 655 | 0.020 |
Why?
|
Outpatients | 1 | 2015 | 1604 | 0.020 |
Why?
|
Down-Regulation | 1 | 2013 | 2940 | 0.020 |
Why?
|
Second-Look Surgery | 1 | 2006 | 27 | 0.020 |
Why?
|
Polyethylene Glycols | 1 | 2012 | 1195 | 0.020 |
Why?
|
Diagnosis, Differential | 1 | 2021 | 13020 | 0.020 |
Why?
|
Transfection | 1 | 2013 | 5764 | 0.020 |
Why?
|
Animals | 3 | 2024 | 169337 | 0.020 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2016 | 2911 | 0.020 |
Why?
|
Research Design | 1 | 2001 | 6210 | 0.010 |
Why?
|
Adenocarcinoma | 2 | 2017 | 6406 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 2635 | 0.010 |
Why?
|
HEK293 Cells | 1 | 2013 | 4291 | 0.010 |
Why?
|
Protein Processing, Post-Translational | 1 | 2012 | 1967 | 0.010 |
Why?
|
Reactive Oxygen Species | 1 | 2012 | 2146 | 0.010 |
Why?
|
Genes, bcl-2 | 1 | 2004 | 119 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2013 | 2056 | 0.010 |
Why?
|
Epithelial Cells | 2 | 2006 | 3695 | 0.010 |
Why?
|
Genes, erbB-2 | 1 | 2004 | 162 | 0.010 |
Why?
|
Multicenter Studies as Topic | 1 | 2008 | 1727 | 0.010 |
Why?
|
Risk Adjustment | 1 | 2007 | 603 | 0.010 |
Why?
|
Histones | 1 | 2013 | 2592 | 0.010 |
Why?
|
Antibodies, Monoclonal | 2 | 2011 | 9261 | 0.010 |
Why?
|
Patient Satisfaction | 1 | 2016 | 3486 | 0.010 |
Why?
|
Radiopharmaceuticals | 1 | 2013 | 2734 | 0.010 |
Why?
|
Drainage | 1 | 2008 | 1184 | 0.010 |
Why?
|
Thrombocytopenia | 1 | 1990 | 1180 | 0.010 |
Why?
|
Phosphoric Monoester Hydrolases | 1 | 2004 | 413 | 0.010 |
Why?
|
Promoter Regions, Genetic | 1 | 2013 | 5801 | 0.010 |
Why?
|
Cell Survival | 1 | 2012 | 5792 | 0.010 |
Why?
|
Patient Compliance | 1 | 2012 | 2693 | 0.010 |
Why?
|
Physical Examination | 1 | 2007 | 1262 | 0.010 |
Why?
|
Phosphorylation | 1 | 2012 | 8326 | 0.010 |
Why?
|
Brachytherapy | 1 | 2008 | 1226 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2016 | 12805 | 0.010 |
Why?
|
Cladribine | 1 | 2000 | 34 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 1992 | 4357 | 0.010 |
Why?
|
Medication Adherence | 1 | 2012 | 2189 | 0.010 |
Why?
|
Central Nervous System Diseases | 1 | 1984 | 523 | 0.010 |
Why?
|
Platelet Count | 2 | 1993 | 784 | 0.010 |
Why?
|
Patient Readmission | 1 | 2013 | 3312 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 3 | 2013 | 20765 | 0.010 |
Why?
|
PTEN Phosphohydrolase | 1 | 2004 | 1119 | 0.010 |
Why?
|
Survivors | 1 | 2009 | 2382 | 0.010 |
Why?
|
Adolescent | 3 | 1998 | 89184 | 0.010 |
Why?
|
Models, Biological | 1 | 1993 | 9493 | 0.010 |
Why?
|
Body Mass Index | 1 | 2015 | 13052 | 0.010 |
Why?
|
Mice | 1 | 2024 | 82017 | 0.010 |
Why?
|
Positron-Emission Tomography | 1 | 2013 | 6670 | 0.010 |
Why?
|
Cough | 1 | 2000 | 599 | 0.010 |
Why?
|
Epithelium | 1 | 2000 | 1609 | 0.010 |
Why?
|
Lymphopenia | 1 | 1997 | 299 | 0.010 |
Why?
|
Postmenopause | 1 | 2004 | 2518 | 0.010 |
Why?
|
Alopecia | 1 | 1999 | 416 | 0.010 |
Why?
|
Kidney | 1 | 1990 | 7064 | 0.010 |
Why?
|
Tumor Suppressor Proteins | 1 | 2004 | 2812 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2004 | 2952 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2021 | 36849 | 0.010 |
Why?
|
Mood Disorders | 1 | 2000 | 1129 | 0.010 |
Why?
|
Dyspnea | 1 | 2000 | 1351 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2009 | 15455 | 0.010 |
Why?
|
Quality of Health Care | 1 | 2007 | 4339 | 0.010 |
Why?
|
Premedication | 1 | 1993 | 246 | 0.010 |
Why?
|
Platinum | 1 | 1993 | 222 | 0.010 |
Why?
|
Neutrophils | 2 | 1993 | 3785 | 0.010 |
Why?
|
Cause of Death | 1 | 2000 | 3728 | 0.010 |
Why?
|
Leukopenia | 1 | 1988 | 212 | 0.000 |
Why?
|
Leukocyte Count | 1 | 1991 | 1605 | 0.000 |
Why?
|
Longitudinal Studies | 1 | 2000 | 14784 | 0.000 |
Why?
|
Heart Rate | 1 | 1993 | 4218 | 0.000 |
Why?
|
Blood Pressure | 1 | 1993 | 8541 | 0.000 |
Why?
|
Cognition Disorders | 1 | 1986 | 3985 | 0.000 |
Why?
|